hk-ipo/data/extracted_text/01779/allotment_results_2026-06-04_2026060402923.txt

--- page 1 ---
1
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange ”)
and Hong Kong Securities Clearing Company Limited ( “HKSCC ”) take no responsibility for the contents of this
announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability
whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this
announcement.
This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States
(including its territories and possessions, any state of the United States and the District of Columbia) or any other
jurisdiction where such distribution is prohibited by law. This announcement does not constitute or form a part of any
offer to sell or solicitation of an offer to buy, to purchase or subscribe for securities nor shall there be any sale of Offer
Shares in the United States or in any other jurisdictions in which such offer or solicitation would be unlawful. The
securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 as
amended from time to time (the “U.S. Securities Act ”) or any state securities law of the United States. The securities
may not be offered, sold, pledged, or transferred within the United States or to, or for the account or benefit of U.S.
persons (as defined in Regulation S under the U.S. Securities Act ( “Regulation S ”)) except pursuant to an exemption
from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in compliance
with any applicable state securities laws. There will be no public offering of securities in the United States. The Offer
Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under
the U.S. Securities Act.
This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase
or subscribe for securities of the Company. This announcement is not a prospectus. Potential investors should read the
prospectus dated May 28, 2026 (the “Prospectus ”) of LongBio Pharma (Suzhou) Co., Ltd. (ᔼᖹ (ᘽψ)ٰ
ʮ̡ ) (the “Company ”) carefully for detailed information about the Company and the Global Offering before
deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Global Offering
should be taken solely in reliance on the information in the Prospectus.
Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those
defined in the Prospectus.
In connection with the Global Offering, Sinolink Securities (Hong Kong) Company Limited, as the stabilizing manager
(the “Stabilizing Manager ”), its affiliates or any person acting for it, may, to the extent permitted by applicable laws
of Hong Kong or elsewhere, over-allocate or effect transactions with a view to stabilizing or maintaining the market
price of the Shares at a level higher than that which might otherwise prevail for a limited period after the Listing
Date. However, there is no obligation on the Stabilizing Manager (its affiliates or any person acting for it) to conduct
any such stabilizing action. Such stabilizing action, if taken, (a) will be conducted at the absolute discretion of the
Stabilizing Manager (its affiliates or any person acting for it) and in what the Stabilizing Manager reasonably regards
as the best interest of the Company, (b) may be discontinued at any time and (c) is required to be brought to an end
within 30 days of the last day for lodging applications under the Hong Kong Public Offering. Such stabilization action,
if commenced, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with
all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules
(Chapter 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Chapter
571 of the Laws of Hong Kong).
Potential investors should be aware that stabilizing action cannot be taken to support the price of the Shares for longer
than the stabilization period which begins on the Listing Date, and is expected to expire on Thursday, July 2, 2026,
the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. After this date, no
further stabilizing action may be taken, demand for the Shares, and therefore the price of the Shares, could fall.
Potential investors of the Offer Shares should note that the Sole Sponsor-Overall Coordinator (for itself and on behalf
of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting
Agreement upon the occurrence of any of the events set out in the paragraph headed “Underwriting {  Underwriting
Arrangements { Hong Kong Public Offering { Grounds for Termination ” in the Prospectus at any time prior to 8:00
a.m. (Hong Kong time) on the Listing Date (which is currently expected to be Friday, June 5, 2026).


--- page 2 ---
2
LongBio Pharma (Suzhou) Co., Ltd.
ʮ̡
(A joint stock company incorporated in the People ’s Republic of China with limited liability)
GLOBAL OFFERING
Number of Offer Shares under the Global
Offering
: 14,193,150 H Shares (subject to the
 Over-allotment Option)
Number of Hong Kong Offer Shares : 1,419,350 H Shares
Number of International Offer Shares : 12,773,800 H Shares (subject to
 the Over-allotment Option)
Offer Price : HK$96.06 per H Share, plus brokerage of
 1.0%, SFC transaction levy of 0.0027%,
 AFRC transaction levy of 0.00015% and
 Stock Exchange trading fee of 0.00565%
Nominal value : RMB1.00 per H Share
Stock Code : 01779
Sole Sponsor, Sole Sponsor-Overall Coordinator, Overall Coordinator, Joint Global
Coordinator, Joint Bookrunner and Joint Lead Manager
Overall Coordinators, Joint Global Coordinators, Joint Bookrunners and
Joint Lead Managers


--- page 3 ---
3
LongBio Pharma (Suzhou) Co., Ltd.
ʮ̡
ANNOUNCEMENT OF ALLOTMENT RESULTS
Warning: In view of high concentration of shareholding in a small number of H
Shareholders, Shareholders and prospective investors should be aware that the price of
the H Shares could move substantially even with a small number of H Shares traded and
should exercise extreme caution when dealing in the H Shares.
SUMMARY
Company information
Stock code 01779
Stock short name LONGBIO-B
Dealings commencement date June 5, 2026*
* see note at the end of the announcement
Price Information
Final Offer Price HK$96.06
Offer Shares and Share Capital
Number of Offer Shares (before exercise of the
 Over-allotment Option) 14,193,150 H Shares
Number of Offer Shares in Hong Kong Public Offering 1,419,350 H Shares
Number of Offer Shares in International Offering
 (before exercise of the Over-allotment Option) 12,773,800 H Shares
Number of issued Shares upon Listing (before exercise of
 the Over-allotment Option) 74,193,150 Shares
Over-allocation
Number of Offer Shares over-allocated 2,128,950 H Shares
Such over-allocation may be covered by exercising the Over-allotment Option or by making purchases in the
secondary market at prices that do not exceed the Offer Price or through deferred delivery or a combination of these
means. In the event the Over-allotment Option is exercised, an announcement will be made on the Stock Exchange ’s
website.
Proceeds
Gross proceeds (Note) HK$1,363.4 million
 Less: Estimated listing expenses payable based on Offer
  Price HK$108.5 million
Net proceeds HK$1,254.9 million
Note: Gross proceeds refer to the amount which the Company is entitled to receive. For details of the use of
proceeds, please refer to the section headed “Future Plans and Use of Proceeds ” of the Prospectus. The
Company will adjust the allocation of the net proceeds from the exercise of the Over-allotment Option (if
any) for the purposes as set out in the section headed “Future Plans and Use of Proceeds ” of the Prospectus
on a pro rata basis.


--- page 4 ---
4
ALLOTMENT RESULTS DETAILS
HONG KONG PUBLIC OFFERING
No. of valid applications 266,377
No. of successful applications 28,057
Subscription level 4,762.58 times
Reallocation N/A
No. of Offer Shares initially available under the Hong Kong
 Public Offering 1,419,350 H Shares
No. of Offer Shares reallocated from the International Offering 0
Final no. of Offer Shares under the Hong Kong Public Offering 1,419,350 H Shares
% of Offer Shares under the Hong Kong Public Offering to the
 Global Offering 10.00%
Note: For details of the final allocation of Offer Shares to the Hong Kong Public Offering, investors can refer to
www.hkeipo.hk/IPOResult to perform a search by identification document number or www.hkeipo.hk/IPOResult
for the full list of allottees.
INTERNATIONAL OFFERING
No. of placees 80
Subscription Level 10.94 times
No. of Offer Shares initially available under the International
 Offering 12,773,800 H Shares
No. of Offer Shares reallocated to the Hong Kong Public Offering 0
Final no. of Offer Shares under the International Offering 12,773,800 H Shares
% of Offer Shares under the International Offering to the Global
 Offering 90.00%
The Directors confirm that, to the best of their knowledge, information and belief, save for
consents under paragraphs 1C(1) and 1C(2) of Appendix F1 to the Listing Rules (the “Placing
Guidelines ”) and under Chapters 2.3 and 4.15 of the Guide for New Listing Applicants ( “Guide ”)
granted by the Stock Exchange to permit the Company to, among other things, allocate certain
Offer Shares in the International Offering to certain close associates of existing Shareholders and
certain connected clients, (i) none of the Offer Shares subscribed by the placees and the public
have been financed directly or indirectly by the Company, any of the Directors, chief executive
of the Company, Controlling Shareholders, substantial Shareholders, existing Shareholders of the
Company or any of its subsidiaries or their respective close associates; and (ii) none of the placees
and the public who have purchased the Offer Shares are accustomed to taking instructions from
the Company, any of the Directors, chief executive of the Company, Controlling Shareholders,
substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their
respective close associates in relation to the acquisition, disposal, voting or other disposition of H
Shares registered in his/her/its name or otherwise held by him/her/it.


--- page 5 ---
5
The placees in the International Offering include the following:
Cornerstone Investors
Investor Note 1
No. of Offer
Shares
allocated
% of Offer
Shares
(assuming the
Over-allotment
Option is
not exercised)
% of total
issued share
capital in the
Company after
the Global
Offering
(assuming the
Over-allotment
Option is
not exercised)
Existing
shareholders
or their close
associates
OrbiMed Genesis Master Fund, L.P. ( “OrbiMed Genesis ”) Note 2 969,900 6.83% 1.31% No
The Biotech Growth Trust PLC ( “BIOG”) Note 2 497,150 3.50% 0.67% No
TruMed Health Innovation Fund LP ( “TruMed Innovation Fund ”) Note 3 692,650 4.88% 0.93% Yes
TruMed Healthcare Master Fund ( “TruMed Master Fund ”) Note 3 285,200 2.01% 0.38% Yes
Shanghai Gaoyi Asset Management Partnership (Limited Partnership)
 ( ɪऎ৷ᆇ༟ପ၍ଣΥྫΆุ (Υྫ )) (“Shanghai Gaoyi ”) and
 Huatai Capital Investment Limited ( “HTCI”) (in connection with
 Huatai Back-to-back TRS and the Huatai Client TRS) 978,050 6.89% 1.32% No
Wisdomshire Asset Management Co., Ltd* (ʮ̡ )
 ( “Wisdomshire AM ”) and HTCI (in connection with Huatai Back-to-back
 TRS and the Huatai Client TRS) 652,000 4.59% 0.88% No
Foresight Global Superior Choice SPC {  Vision Fund 1 SP ( “Vision Fund 1 ”) Note 4 474,650 3.34% 0.64% No
Foresight Global Superior Choice SPC {  Global Superior Choice Fund 1 SP
 ( “GSC Fund 1 ”) Note 4 258,900 1.82% 0.35% No
Foresight Global Superior Choice SPC {  Horizon Fund 1 SP
 ( “Horizon Fund 1 ”) Note 4 40,750 0.29% 0.05% No
Foresight Global Superior Choice SPC {  Horizon Next Fund SP
 ( “Horizon Next Fund ”) Note 4 40,750 0.29% 0.05% No
Fullgoal Fund Management Co., Ltd. (ʮ̡ )
 ( “Fullgoal Fund ”) Note 5 685,450 4.83% 0.92% No
Fullgoal Asset Management (HK) Limited ( బ਷༟ପ၍ଣ (ಥ)ʮ̡ )
 ( “Fullgoal HK ”) Note 5 129,550 0.91% 0.17% No
Value Partners Hong Kong Limited ( “VPHKL”) Note 6 570,400 4.02% 0.77% No
Value Partners Limited ( “VPL”) Note 6 81,500 0.57% 0.11% No
Greater Bay Area Development Fund Management Limited for and on behalf of the
 managed account of Mega Prime Development Limited ( “Mega Prime ”) 407,500 2.87% 0.55% No
FR M CONSULTING CO., LTD ( “FR M ”) 163,000 1.15% 0.22% No
Yuanfeng Future Growth Private Equity Securities Investment Fund*
 (ږ“( ) Yuanfeng Future Growth Fund ”)
 and China Galaxy International Investment Company Limited ( “CGII”)
 (in connection with the Yuanfeng OTC Swaps) 163,000 1.15% 0.22% No
Total 7,090,400 49.96% 9.56%


--- page 6 ---
6
Notes:
(1) For further details of the Cornerstone Investors, please refer to the section headed “Cornerstone Investors ” in
the Prospectus.
(2) As disclosed in the Prospectus, OrbiMed Genesis is an exempted limited partnership incorporated in the
Cayman Islands. OrbiMed Genesis GP LLC ( “Genesis GP ”) is the general partner of OrbiMed Genesis.
OrbiMed Advisors LLC ( “OrbiMed Advisors ”) is the managing member of Genesis GP. BIOG is a publicly
listed trust organized under the laws of England. OrbiMed Capital LLC ( “OrbiMed Capital ”) is the portfolio
manager of BIOG. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through
a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, all of whom
are Independent Third Parties. The management committee has sole discretion in exercising such voting and
investment power on behalf of OrbiMed Advisors and OrbiMed Capital.
(3) As disclosed in the Prospectus, TruMed Innovation Fund is a limited partnership incorporated in the Cayman
Island. Its general partner is TruMed Health Innovation Fund GP Limited, which is wholly owned by Ms.
Ting Wang. TruMed Master Fund is a healthcare-focused pooled investment fund managed by TruMed
Investment Management Limited as investment manager with discretionary authority. TruMed Investment
Management Limited is wholly owned by Ms. Ting Wang. TruMed Innovation Fund and TruMed Master
Fund are therefore under the common control of Ms. Ting Wang. Each of TruMed Innovation Fund and
TruMed Master Fund is a close associate of Hainan Renze Zhenji Venture Capital Fund Partnership Enterprise
(Limited Partnership) (Υྫ), which holds approximately 0.30%
of the total issued Shares immediately prior to the Global Offering. The Stock Exchange has given consent
under paragraph 1C(2) of the Placing Guidelines to permit each of TruMed Innovation Fund and TruMed
Master Fund to participate in the International Offering as a Cornerstone Investor. Please refer to the section
headed “Waivers from Strict Compliance with Listing Rules and Exemption from Strict Compliance with the
Companies (Winding Up and Miscellaneous Provisions) Ordinance ” in the Prospectus and “Others/Additional
Information ” in this announcement for details.
(4) As disclosed in the Prospectus, Vision Fund 1, GSC Fund 1, Horizon Fund 1 and Horizon Next Fund are all
sub funds of Foresight Global Superior Choice SPC.
(5) As disclosed in the Prospectus, Fullgoal HK is a wholly owned subsidiary of Fullgoal Fund.
(6) As disclosed in the Prospectus, VPHKL and VPL are wholly-owned subsidiaries of Value Partners Group
Limited, a company listed on the Stock Exchange (stock code: 806). Each of VPHKL and VPL is a connected
client of GF Securities (Hong Kong) Brokerage Limited. The Stock Exchange has given consent under
paragraph 1C(1) of the Placing Guidelines in relation to the allocation of Offer Shares to each of VPHKL
and VPL as Cornerstone Investors. Please refer to the section headed “Waivers from Strict Compliance with
Listing Rules and Exemption from Strict Compliance with the Companies (Winding Up and Miscellaneous
Provisions) Ordinance ” in the Prospectus and “Others/Additional Information ” in this announcement for
details.


--- page 7 ---
7
Allottees with Waivers/Consents Obtained
Investor
No. of Offer
Shares
allocated
% of Offer
Shares
(assuming the
Over-allotment
Option is
not exercised)
% of total issued
share capital in
the Company
after the
Global Offering
(assuming the
Over-allotment
Option is
not exercised) Relationship
Allottees with consent under paragraph 1C(2) of the Placing Guidelines under Chapters 2.3 and 4.15 of the Guide in relation to allocation of Offer
Shares to close associates of existing Shareholders Note 1
TruMed Innovation Fund 692,650 4.88% 0.93%
A close associate of an
existing Shareholder
TruMed Master Fund 285,200 2.01% 0.38%
A close associate of an
existing Shareholder
O F CAPITAL TECH LPF ( “OFC Tech ”) 16,100 0.11% 0.02%
A close associate of an
existing Shareholder
Changshu Kunsheng Equity Investment Fund Partnership Enterprise
 (Limited Partnership) (ΥྫΆุ
 (Υྫ )) ( “Changshu Kunsheng ”) Note 2 806,850 5.68% 1.09%
A close associate of an
existing Shareholder
Changshu Guofa Venture Capital Co., Ltd. ( ੬ᆞ̹਷೯௴ุҳ༟
 ʮ̡ ) (“Changshu Guofa ”) Note 2 403,400 2.84% 0.54%
A close associate of an
existing Shareholder
Allottees with consents under paragraph 1C(1) of the Placing Guidelines and Chapter 4.15 of the Guide in relation to allocations to connected clients  Note 3
VPHKL 570,400 4.02% 0.77% A connected client
VPL 81,500 0.57% 0.11% A connected client
GF International Investment Management Limited
 ( “GF International Investment ”) Note 4 806,850 5.68% 1.09% A connected client
E Fund Management Co., Ltd. ( “E Fund ”) Note 5 57,450 0.40% 0.08% A connected client
E Fund Management (Hong Kong) Co., Ltd. ( “E Fund HK ”) Note 5 7,100 0.05% 0.01% A connected client
GF Securities Asset Management (Guangdong) Co., Ltd.
 ( “GF Securities AM ”) Note 4 8,500 0.06% 0.01% A connected client
Orient Asset Management (Hong Kong) Limited ( “Orient AM ”) 800 0.01% 0.001% A connected client


--- page 8 ---
8
Investor
No. of Offer
Shares
allocated
% of Offer
Shares
(assuming the
Over-allotment
Option is
not exercised)
% of total issued
share capital in
the Company
after the
Global Offering
(assuming the
Over-allotment
Option is
not exercised) Relationship
Notes:
(1) The Stock Exchange has given a consent under paragraph 1C(2) of the Placing Guidelines and Chapters
2.3 and 4.15 of Guide permit Offer Shares be placed the above placees who are close associates of existing
Shareholders. Please refer to the section headed “Others/Additional Information ” in this announcement.
(2) Changshu Kunsheng is a limited partnership established in the PRC, whose general partner is Changshu
Kaisheng Southeast Entrepreneurship Investment Management Co., Ltd. (ʮ
̡) ( “Changshu Kaisheng ”) with 1% partnership interest therein. Changshu Guofa is a company established
in the PRC with limited liability. Changshu Kaisheng and Changshu Guofa are all indirectly wholly-owned
by the Bureau of Finance of Changshu (Changshu Municipal Government State-owned Assets Supervision
and Administration Office) (҅ (܃“( )) Changshu SASAO ”).
Changshu Kunsheng and Changshu Guofa subscribed for the H Shares through certain Qualified Domestic
Institutional Investors.
(3) For details of the consent under paragraph 1C(1) of the Placing Guidelines and Chapter 4.15 of the Guide in
relation to allocations to connected clients, please refer to the section headed “Others/Additional Information ”
in this announcement.
(4) GF International Investment is an indirect non-wholly owned subsidiary of GF Securities Co., Ltd. ( ᄿ೯൛
ʮ̡ ) ( “GF Securities ”), a company listed on the Shezhen Stock Exchange (stock code: 000776.
SZ). GF Securities AM is a direct wholly-owned subsidiary of GF Securities. Please refer to the section
headed “Others/Additional Information ” in this announcement for details.
(5) E Fund HK is a wholly-owned subsidiary of E Fund. Please refer to the section headed “Others/Additional
Information ” in this announcement for details.


--- page 9 ---
9
LOCK-UP UNDERTAKINGS
Cornerstone Investors
Name
Number of Shares
held in the Company
subject to lock-up
undertakings
upon Listing
% of total issued
H Shares after the
Global Offering
subject to lock-up
undertakings upon
Listing (assuming
the Over-allotment
Option is not
exercised)
% of total issued
share capital in the
Company subject to
lock-up undertakings
upon Listing
(assuming the Over-
allotment Option is
not exercised)
Last day subject
to the lock-up
undertakings Note 1
OrbiMed Genesis 969,900 H Shares 1.33% 1.31% December 4, 2026
BIOG 497,150 H Shares 0.68% 0.67% December 4, 2026
TruMed Innovation Fund 692,650 H Shares 0.95% 0.93% December 4, 2026
TruMed Master Fund 285,200 H Shares 0.39% 0.38% December 4, 2026
Shanghai Gaoyi and HTCI (in connection with Huatai
 Back-to-back TRS and the Huatai Client TRS) 978,050 H Shares 1.34% 1.32% December 4, 2026
Wisdomshire AM and HTCI (in connection with
 Huatai Back-to-back TRS and the Huatai
 Client TRS) 652,000 H Shares 0.89% 0.88% December 4, 2026
Vision Fund 1 474,650 H Shares 0.65% 0.64% December 4, 2026
GSC Fund 1 258,900 H Shares 0.35% 0.35% December 4, 2026
Horizon Fund 1 40,750 H Shares 0.06% 0.05% December 4, 2026
Horizon Next Fund 40,750 H Shares 0.06% 0.05% December 4, 2026
Fullgoal Fund 685,450 H Shares 0.94% 0.92% December 4, 2026
Fullgoal HK 129,550 H Shares 0.18% 0.17% December 4, 2026
VPHKL 570,400 H Shares 0.78% 0.77% December 4, 2026
VPL 81,500 H Shares 0.11% 0.11% December 4, 2026
Mega Prime 407,500 H Shares 0.56% 0.55% December 4, 2026
FR M 163,000 H Shares 0.22% 0.22% December 4, 2026
Yuanfeng Future Growth Fund and CGII
 (in connection with the Yuanfeng OTC Swaps) 163,000 H Shares 0.22% 0.22% December 4, 2026
Subtotal 7,090,400 H Shares 9.72% 9.56%
Note:
(1) In accordance with the relevant cornerstone investment agreements, the required lock-up ends on December
4, 2026, being six months following the Listing Date. The Cornerstone Investors will cease to be prohibited
from disposing of or transferring H Shares subscribed for pursuant to the relevant cornerstone investment
agreements after the indicated date.


--- page 10 ---
10
Controlling Shareholders
Name
Number of
Shares held in
the Company
subject to lock-up
undertakings upon
Listing
% of total issued
H Shares after the
Global Offering
subject to lock-up
undertakings upon
Listing (assuming
the Over-allotment
Option is not
exercised)
% of total issued
share capital in
the Company
subject to lock-up
undertakings upon
Listing (assuming
the Over-allotment
Option is not
exercised)
Last day subject
to the lock-up
undertakings Note 1
Liu Heng ( ᄎ㛬) 8,447,692 H Shares 11.58% 11.39% June 4, 2027
Sun Bill Nai-chau
(ɗ൴) 6,668,921 H Shares 9.14% 8.99% June 4, 2027
Suzhou Taiwu Enterprise
Management Partnership
(Limited Partnership)
(Άุ၍ଣΥྫ
Άุ(Υྫ )) 4,899,364 H Shares 6.72% 6.60% June 4, 2027
Sun Cecily Rou-yun
(ڄ߰3,643,748 H Shares 5.00% 4.91% June 4, 2027
Shanghai Rising Suns
Biomedical Inc. ( ɪऎ
ʮ̡ ) 2,154,243 H Shares 2.95% 2.90% June 4, 2027
PharMab, Inc. ( ϛശ
(ɪऎ)೯ʕː
ʮ̡ ) 683,191 H Shares 0.94% 0.92% June 4, 2027
Total 26,497,159 H Shares 36.33% 35.71%
Note:
(1) The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law. The
required lock-up for the Controlling Shareholders ends on June 4, 2027, being twelve months following
the Listing Date. Pursuant to Rule 10.07 of the Listing Rules, each of the Controlling Shareholders has
undertaken to the Stock Exchange and the Company that, he, she or it shall comply with the applicable lock-
up requirements. For further details, please refer to the section headed “Underwriting – Undertakings to
the Stock Exchange Pursuant to the Listing Rules – Undertakings by our Controlling Shareholders ” in the
Prospectus.


--- page 11 ---
11
Other Existing Shareholders (including the Pre-IPO Investors as defined in the “History,
Development and Corporate Structure ” section of the Prospectus)
Name
Number of Shares
held in the Company
subject to lock-up
undertakings upon
Listing
Number of H Shares
held in the Company
as a % of total issued
H Shares after the
Global Offering
subject to lock-up
undertakings upon
Listing (assuming
the Over-allotment
Option is not
exercised)
% of total issued
share capital in
the Company
subject to lock-
up undertakings
upon Listing
(assuming the
Over-allotment
Option is not
exercised)
Last day subject
to the lock-up
undertakings
Note 1  and  Note 2
Huzhou Youxing Venture Capital
 Partnership Enterprise (Limited
 Partnership) (௴ุҳ
 ༟ΥྫΆุ (Υྫ ))
 ( “Huzhou Youxing ”) Note 3 7,021,810 H Shares 9.63% 9.46% June 4, 2027
Suzhou Youxin Venture Capital
 Partnership Enterprise (Limited
 Partnership) (௴ุҳ༟
 ΥྫΆุ (Υྫ )
 ( “Suzhou Youxin ”) Note 3 3,203,667 H Shares 4.39% 4.32% June 4, 2027
Suzhou Lianrui Venture Capital
 Partnership Enterprise (Limited
 Partnership) ( ᘽψஹቚ௴ุҳ༟
 ΥྫΆุ (Υྫ ))
 ( “Suzhou Lianrui ”) Note 3 1,641,884 H Shares 2.25% 2.21% June 4, 2027
Huzhou Youcheng Venture Capital
 Partnership Enterprise (Limited
 Partnership ( ಳψʾϓ௴ุҳ༟
 ΥྫΆุ (Υྫ ))
 ( “Huzhou Youcheng ”) Note 3 866,867 H Shares 1.19% 1.17% June 4, 2027
Fuhai Ancheng Bohui (Bozhou)
 Healthcare Equity Investment
 Fund Partnership Enterprise
 (Limited Partnership) ( బऎτ༐௹
 ฯ(ψ)ږ
 ΥྫΆุ (Υྫ ))
 ( “OFC Bohui Fund ”) Note 4 3,077,490 H Shares 4.22% 4.15% June 4, 2027
China SME Development Fund
 (Chengdu) Jiaozi Venture Capital
 Investment Partnership Enterprise
 (Limited Partnership) ( ʕʃΆุ
 ږ(ϓே)ʹɿ௴ุҳ༟
 ΥྫΆุ(Υྫ))
 ( “OFC Jiaozi Fund ”) Note 4 1,171,447 H Shares 1.61% 1.58% June 4, 2027
Huzhou Yongshi Huijin Venture
 Capital Partnership Enterprise
 (Limited Partnership) ( ಳψ͑ͩ
 ௴ุҳ༟ΥྫΆุ (Υྫ ))
 ( “Yongshi Huijin ”) Note 5
1,025,832 (including
512,916 H Shares) 0.70% 1.38% June 4, 2027


--- page 12 ---
12
Name
Number of Shares
held in the Company
subject to lock-up
undertakings upon
Listing
Number of H Shares
held in the Company
as a % of total issued
H Shares after the
Global Offering
subject to lock-up
undertakings upon
Listing (assuming
the Over-allotment
Option is not
exercised)
% of total issued
share capital in
the Company
subject to lock-
up undertakings
upon Listing
(assuming the
Over-allotment
Option is not
exercised)
Last day subject
to the lock-up
undertakings
Note 1  and  Note 2
Huzhou Yongshi Weizhen Venture
 Capital Investment Partnership
 Enterprise (Limited Partnership)
 ( ಳψ͑ͩਬॆ௴ุҳ༟ΥྫΆุ
 (Υྫ )
 ( “Yongshi Weizhen ”) Note 5
1,499,932 (including
749,966 H Shares) 1.03% 2.02% June 4, 2027
HLC VGC Partners HK II Limited
 ( “HLC”) Note 6 1,290,964 H Shares 1.77% 1.74% June 4, 2027
Qingdao Hongyi Investment
 Partnership (Limited Partnership)
 (̾⥙ҳ༟ΥྫΆุ (ࠢ
 Υྫ)) ( “Qingdao Hongyi ”) Note 6 1,099,710 H Shares 1.51% 1.48% June 4, 2027
QM282 Limited 1,921,283 H Shares 2.63% 2.59% June 4, 2027
Qingdao CSPC Sangel New Drug
 Investment Partnership Enterprise
 (Limited Partnership) (ͩᖹ̀
 ᐘอᖹҳ༟ΥྫΆุ (Υྫ )) 1,538,745 H Shares 2.11% 2.07% June 4, 2027
Shanghai Lingang Pioneer Innovation
 Private Equity Investment Fund
 Partnership L.P. ( ɪऎᑗಥ
 ږ
 ΥྫΆุ (Υྫ )) 1,045,922 H Shares 1.43% 1.41% June 4, 2027
Changshu Southeast Industrial
 Investment Co., Ltd. (ی؇
 ʮ̡ )
 ( “Southeast Investment ”) Note 7 1,025,832 H Shares 1.41% 1.38% June 4, 2027
Changshu Wuyue Angel Venture
 Capital Partnership Enterprise
 (Limited Partnership) ( ੬ᆞю൳
 ˂Դ௴ุҳ༟ΥྫΆุ (Υྫ ))
 ( “Changshu Wuyue Angel ”) Note 7 390,484 H Shares 0.54% 0.53% June 4, 2027
Shanxi Securities Alternative Investment
 Ltd (ʮ̡) 954,287 H Shares 1.31% 1.29% June 4, 2027
Anhui Anyuan Modern Health
 Industry Investment Center
 (Limited Partnership) ( τᏏτʩତ
 ˾਄ੰପุҳ༟ʕː (Υྫ )) 820,662 H Shares 1.13% 1.11% June 4, 2027


--- page 13 ---
13
Name
Number of Shares
held in the Company
subject to lock-up
undertakings upon
Listing
Number of H Shares
held in the Company
as a % of total issued
H Shares after the
Global Offering
subject to lock-up
undertakings upon
Listing (assuming
the Over-allotment
Option is not
exercised)
% of total issued
share capital in
the Company
subject to lock-
up undertakings
upon Listing
(assuming the
Over-allotment
Option is not
exercised)
Last day subject
to the lock-up
undertakings
Note 1  and  Note 2
Hangzhou Beicheng Venture Capital
 Partnership (Limited Partnership
 Enterprise) (ψԎዐ௴ุҳ༟
 ΥྫΆุ (Υྫ )) 747,085 H Shares 1.02% 1.01% June 4, 2027
Changshu Sanyi No. 1 Venture Capital
 Partnership Enterprise (Limited
 Partnership) (ఠ໮௴ุ
 ҳ༟ΥྫΆุ (Υྫ )) 727,654 H Shares 1.00% 0.98% June 4, 2027
Hangzhou Qiming Rongjing Equity
 Investment Partnership Enterprise
 (Limited Partnership) (׼
 ᛆҳ༟ΥྫΆุ (Υྫ ))
 ( “Qiming Rongjing ”) Note 8 384,255 H Shares 0.53% 0.52% June 4, 2027
Suzhou Qiming Rongqian Equity
 Investment Partnership (Limited
 Partnership Enterprise) (׼
 ᛆҳ༟ΥྫΆุ (Υྫ ))
 ( “Qiming Rongqian ”) Note 8 256,176 H Shares 0.35% 0.35% June 4, 2027
Hefei Hongta Industrial Investment
 Partnership (Limited Partnership)
 (̾᧎ପุҳ༟ΥྫΆุ
 (Υྫ )) 585,726 H Shares 0.80% 0.79% June 4, 2027
Shenzhen Sangel Shunchuang
 Biomedical Angel Investment
 Partnership Enterprise (Limited
 Partnership) (ي
 ᔼᐕ˂Դҳ༟ΥྫΆุ (Υྫ )) 512,913 H Shares 0.70% 0.69% June 4, 2027
Shenzhen Xinsheng Huachuang
 Enterprise Management Partnership
 (Limited Partnership) ( ଉέ̹อ͛
 ശ௴Άุ၍ଣΥྫΆุ (Υྫ )) 512,913 H Shares 0.70% 0.69% June 4, 2027
Hainan Renze Zhenji Venture Capital
 Fund Partnership Enterprise
 (Limited Partnership) (ʠዣॆ
 ΥྫΆุ
 (Υྫ )) 179,301 H Shares 0.25% 0.24% June 4, 2027
Total
33,502,841
(including
32,239,959 H
Shares) 44.21% 45.16%


--- page 14 ---
14
Notes:
(1) Under the applicable PRC laws, all existing Shareholders (including Pre-IPO Investors) are subject to a lock-
up period of twelve months following the Listing Date.
(2) The numbers of Shares held by OFC Bohui Fund, OFC Jiaozi Fund, Southeast Investment, Changshu Wuyue
Angel and Hainan Renze in the table above do not take into account the Shares to be subscribed by their
respective close associates in the Global Offering. The Company has applied to the Stock Exchange for, and
the Stock Exchange has given to the Company, a consent under paragraph 1C(2) of the Placing Guidelines
permit the Company to allocate such Offer Shares in the International Offering to their respective close
associates. For details, please refer to the sections headed “Allottees with Waivers/Consents Obtained ” and
“Others/Additional Information ” in this announcement.
(3) As disclosed in the Prospectus, each of Huzhou Youxing, Suzhou Youxin, Suzhou Lianrui and Huzhou
Youcheng is a limited partnership established in the PRC, and the executive partner and fund manager of
which is Shanghai Tongrui Investment Management Company Limited.
(4) As disclosed in the Prospectus, OFC Bohui Fund and OFC Jiaozi Fund, both of which are limited partnerships
established in the PRC, are venture capital investment funds whose investment and asset management
affairs are managed and controlled by its respective fund managers, being Oriental Fortune (Wuhu) Equity
Investment Fund Management Enterprise (Limited Partnership) (˙బऎ (ጾಳ)၍ଣΆุ
(Υྫ )) ( “OFC Wuhu ”) and Shenzhen Oriental Fortune Venture Capital Investment Management Co.,
Ltd. (ʮ̡ ) ( “OFC VC Investment ”). Each of OFC VC Investment and
OFC Wuhu is a direct or indirect wholly owned subsidiary of Shenzhen Oriental Fortune Capital Investment
Management Co., Ltd. (ʮ̡ ) ( “Oriental Fortune Capital ”). OFC Wuhu
is owned by Oriental Fortune Capital and OFC VC Investment as to 95% and 5%, respectively, and OFC VC
Investment is in turn wholly owned by Oriental Fortune Capital.
(5) As disclosed in the Prospectus, each of Yongshi Huijin and Yongshi Weizhen is limited partnership
established in the PRC, and the executive partner and fund manager of which is Huzhou Yongshi Equity
Investment Management Co., Ltd. (ʮ̡ ).
(6) As disclosed in the Prospectus, HLC is a company incorporated in Hong Kong with limited liability, and it
is wholly owned by HLC VGC Fund IV L.P.. HLC VGC Fund IV L.P. is an exempted limited partnership
established under the laws of the Cayman Islands and is ultimately managed by its general partner HLC VGC
GP IV Limited, and in turn ultimately controlled by Mr. WANG Hui ( ˮฯ). Qingdao Hongyi is a limited
partnership established in the PRC and managed by its executive partner, Shanghai Hehong Jinghui Equity
Investment Management Co., Ltd. (ʮ̡ ) ( “Shanghai Hehong Jinghui ”).
Shanghai Hehong Jinghui is also ultimately controlled by Mr. WANG Hui ( ˮฯ) and is owned as to 72% by
him.
(7) As disclosed in the Prospectus, Southeast Investment is a company established in the PRC with limited
liability. It is owned by Changshu Southeast Investment Holding Co., Ltd. (ʮ̡ )
as to 99.96%, which is in turn indirectly wholly owned by Changshu SASAO. Changshu Wuyue Angel is a
limited partnership established in the PRC. Among the limited partners of Changshu Wuyue Angel, Changshu
Investment Holdings Group Co., Ltd. (ʮ̡ ) holds approximately 52.89% of the
partnership interests. Changshu Investment Holdings Group Co., Ltd. is wholly owned by Changshu State-
owned Capital Investment and Operation Group Co., Ltd. (ʮ̡ ) which is
in turn wholly owned by Changshu SASAO. The executive partner of Changshu Wuyue Angel is Changshu
Qixin Venture Capital Partnership (Limited Partnership) ( ੬ᆞ઼อ௴ุҳ༟ΥྫΆุ (Υྫ )), which
is owned as to 35% by Changshu Guofa as its executive partner and as to 35% by SIP Oriza Seed Fund
Management Co., LTD. (ʮ̡ ). Changshu Guofa is indirectly
wholly-owned by the Changshu SASAO.
(8) As disclosed in the Prospectus, Qiming Rongjing and Qiming Rongqian are limited partnerships established
in the PRC, with their general partner being Suzhou Qikun Venture Capital Partnership (Limited Partnership)
(ᘽψ઼տ௴ุҳ༟ΥྫΆุ (Υྫ )).


--- page 15 ---
15
PLACEE CONCENTRATION ANALYSIS
Placees
* Number of H
Shares allotted
Allotment as %
of International
Offering
(assuming no
exercise of the
Over-allotment
Option)
Allotment as %
of International
Offering
(assuming the
Over-allotment
Option is
exercised and
new H Shares
are issued)
Allotment as %
of total Offer
Shares
(assuming no
exercise of the
Over-allotment
Option)
Allotment as %
of total Offer
Shares
(assuming the
Over-allotment
Option is
exercised and
new H Shares
are issued)
Number of
H Shares held
upon Listing
% of total
issued share
capital upon
Listing
(assuming no
exercise of the
Over-allotment
Option)
% of total
issued share
capital upon
Listing
(assuming the
Over-allotment
Option is
exercised and
new H Shares
are issued)
Top 1 1,467,050 11.5% 9.8% 10.3% 9.0% 1,467,050 2.0% 1.9%
Top 5 5,513,100 43.2% 37.0% 38.8% 33.8% 6,929,416 9.3% 9.1%
Top 10 9,144,850 71.6% 61.4% 64.4% 56.0% 10,561,166 14.2% 13.8%
Top 25 13,735,500 107.5% 92.2% 96.8% 84.2% 15,151,816 20.4% 19.9%
Note:
* Ranking of placees is based on the number of H Shares allotted to the placees.
H SHAREHOLDER CONCENTRATION ANALYSIS
H Shareholders
* Number of
H Shares
allotted
Allotment
as % of
International
Offering
(assuming no
exercise of
the Over-
allotment
Option)
Allotment
as % of
International
Offering
(assuming the
Over-allotment
Option is
exercised and
new H Shares
are issued)
Allotment as
% of total
Offer Shares
(assuming no
exercise of
the Over-
allotment
Option)
Allotment as
% of total
Offer Shares
(assuming
the Over-
allotment
Option is
exercised and
new H
Shares are
issued)
Number of
H Shares
held upon
Listing
% of total
number
of issued
H Shares
upon Listing
(assuming
no exercise
of the Over-
allotment
Option)
% of total
number of
issued
H Shares
upon Listing
(assuming the
Over-allotment
Option is
exercised and
new H Shares
are issued)
Number
of Shares
held upon
Listing
Top 1 – 0.0% 0.0% 0.0% 0.0% 26,497,159 36.3% 35.3% 26,497,159
Top 5 1,226,350 9.6% 8.2% 8.6% 7.5% 48,513,664 66.5% 64.6% 48,513,664
Top 10 3,671,250 28.7% 24.6% 25.9% 22.5% 55,860,775 76.6% 74.4% 57,123,657
Top 25 9,812,850 76.8% 65.8% 69.1% 60.1% 67,524,142 92.6% 90.0% 68,787,024
Note:
* Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.


--- page 16 ---
16
SHAREHOLDER CONCENTRATION ANALYSIS
All Shareholders
* Number of
H Shares
allotted
Allotment as %
of International
Offering
(assuming no
exercise of the
Over-allotment
Option)
Allotment as %
of International
Offering
(assuming the
Over-allotment
Option is
exercised and
new H Shares
are issued)
Allotment as
% of total
Offer Shares
(assuming no
exercise of the
Over-allotment
Option)
Allotment as %
of total Offer
Shares (assuming
the Over-
allotment Option
is exercised and
new H Shares
are issued)
Number of
Shares held
upon Listing
% of total
issued share
capital upon
Listing
(assuming no
exercise of the
Over-allotment
Option)
% of total
issued share
capital upon
Listing
(assuming the
Over-allotment
Option is
exercised and
new H Shares
are issued)
Top 1 – 0.0% 0.0% 0.0% 0.0% 26,497,159 35.7% 34.7%
Top 5 1,226,350 9.6% 8.2% 8.6% 7.5% 48,513,664 65.4% 63.6%
Top 10 3,671,250 28.7% 24.6% 25.9% 22.5% 57,123,657 77.0% 74.8%
Top 25 9,812,850 76.8% 65.8% 69.1% 60.1% 68,787,024 92.7% 90.1%
Note:
* Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholders upon
Listing.


--- page 17 ---
17
BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING
Subject to the satisfaction of the conditions set out in the Prospectus, valid applications made by
the public will be conditionally allocated on the basis set out below:
Pool A
Number
of H Shares
applied for
Number
of valid
applications Basis of allocation/ballot
Approximate
percentage
allotted of the
total number
of H Shares
applied for
50 51,154 1,024 out of 51,154 applicants to receive 50 H Shares 2.00%
100 27,227 679 out of 27,227 applicants to receive 50 H Shares 1.25%
150 5,797 165 out of 5,797 applicants to receive 50 H Shares 0.95%
200 5,425 169 out of 5,425 applicants to receive 50 H Shares 0.78%
250 4,451 149 out of 4,451 applicants to receive 50 H Shares 0.67%
300 3,614 128 out of 3,614 applicants to receive 50 H Shares 0.59%
350 2,817 105 out of 2,817 applicants to receive 50 H Shares 0.53%
400 2,587 100 out of 2,587 applicants to receive 50 H Shares 0.48%
450 1,718 69 out of 1,718 applicants to receive 50 H Shares 0.45%
500 17,860 741 out of 17,860 applicants to receive 50 H Shares 0.41%
600 2,605 115 out of 2,605 applicants to receive 50 H Shares 0.37%
700 2,131 99 out of 2,131 applicants to receive 50 H Shares 0.33%
800 2,255 109 out of 2,255 applicants to receive 50 H Shares 0.30%
900 2,417 121 out of 2,417 applicants to receive 50 H Shares 0.28%
1,000 12,501 647 out of 12,501 applicants to receive 50 H Shares 0.26%
1,500 5,728 337 out of 5,728 applicants to receive 50 H Shares 0.20%
2,000 5,249 338 out of 5,249 applicants to receive 50 H Shares 0.16%
2,500 3,749 259 out of 3,749 applicants to receive 50 H Shares 0.14%
3,000 3,635 267 out of 3,635 applicants to receive 50 H Shares 0.12%
3,500 2,555 197 out of 2,555 applicants to receive 50 H Shares 0.11%
4,000 2,555 205 out of 2,555 applicants to receive 50 H Shares 0.10%
4,500 2,094 175 out of 2,094 applicants to receive 50 H Shares 0.09%
5,000 4,918 424 out of 4,918 applicants to receive 50 H Shares 0.09%
6,000 3,647 333 out of 3,647 applicants to receive 50 H Shares 0.08%
7,000 2,614 251 out of 2,614 applicants to receive 50 H Shares 0.07%
8,000 2,314 232 out of 2,314 applicants to receive 50 H Shares 0.06%
9,000 2,165 225 out of 2,165 applicants to receive 50 H Shares 0.06%
10,000 14,544 1,559 out of 14,544 applicants to receive 50 H Shares 0.05%
20,000 9,347 1,249 out of 9,347 applicants to receive 50 H Shares 0.03%
30,000 7,263 1,103 out of 7,263 applicants to receive 50 H Shares 0.03%
40,000 5,370 894 out of 5,370 applicants to receive 50 H Shares 0.02%
50,000 9,667 1,726 out of 9,667 applicants to receive 50 H Shares 0.02%
Total 231,973 Total number of Pool A successful applicants: 14,194


--- page 18 ---
18
Pool B
Number
of H Shares
applied for
Number
of valid
applications Basis of allocation/ballot
Approximate
percentage
allotted of the
total number
of H Shares
applied for
60,000 8,776 2,107 out of 8,776 applicants to receive 50 H Shares 0.02%
70,000 3,101 824 out of 3,101 applicants to receive 50 H Shares 0.02%
80,000 2,312 671 out of 2,312 applicants to receive 50 H Shares 0.02%
90,000 1,923 603 out of 1,923 applicants to receive 50 H Shares 0.02%
100,000 8,879 2,980 out of 8,879 applicants to receive 50 H Shares 0.02%
200,000 4,254 2,249 out of 4,254 applicants to receive 50 H Shares 0.01%
300,000 1,758 1,213 out of 1,758 applicants to receive 50 H Shares 0.01%
400,000 976 813 out of 976 applicants to receive 50 H Shares 0.01%
500,000 630 608 out of 630 applicants to receive 50 H Shares 0.01%
600,000 429 50 H Shares plus 38 out of 429 applicants to
 receive an additional 50 H Shares
0.01%
709,650 1,366 50 H Shares plus 292 out of 1,366 applicants to
 receive an additional 50 H Shares
0.01%
Total 34,404 Total number of Pool B successful applicants: 13,863
As of the date of this announcement, the relevant subscription monies previously deposited in the
designated nominee accounts have been remitted back to the accounts of all HKSCC participants.
Investors should contact their relevant brokers for any inquiries.
COMPLIANCE WITH LISTING RULES AND GUIDANCE
The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of
which consent has been obtained, the Company has complied with the Listing Rules and guidance
materials in relation to the placing, allotment and listing of the Company ’s H Shares.
The Directors confirm that, to the best of their knowledge, the consideration paid by the placees
or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or
purchased by them was the same as the Offer Price in addition to any brokerage, AFRC transaction
levy, SFC transaction levy and Stock Exchange trading fee payable.


--- page 19 ---
19
OTHERS/ADDITIONAL INFORMATION
Allocation of Offer Shares to Certain Existing Shareholders and/or Their Close Associates
As Cornerstone Investors
The Company has sought, and the Stock Exchange has given, a consent under paragraph 1C(2) of
the Placing Guidelines to permit TruMed Master Fund and TruMed Innovation Fund (collectively,
the “TruMed Funds ”) to participate in the Global Offering as Cornerstone Investors on the
following basis as set out in Paragraph 18 of Chapter 2.3 and Chapter 4.15 of the Guide, subject to
the conditions as follows:
(a) the Company will comply with the public float requirement under Rule 19A.13A and the free
float requirement under Rule 19A.13C of the Listing Rules;
(b) the Offer Shares to be subscribed by and allocated to TruMed Master Fund and TruMed
Innovation Fund (each a close associate of an existing Shareholder) as cornerstone investors
under the Global Offering will be at the Offer Price and on substantially the same terms as
other cornerstone investors (including being subject to a six-month lock up arrangement
following the Listing), and TruMed Funds will pay and settle in full for the Offer Shares
before dealings commence on the Listing Date;
(c) the Company, the Sole Sponsor and the Overall Coordinators confirm that no preferential
treatment has been, nor will be, given to each of TruMed Funds as a cornerstone investor by
virtue of its relationship with the Company in any allocation in the Global Offering, other
than the preferential treatment of assured entitlement under the cornerstone investment with
TruMed Funds which follows the principles set out in Chapters 2.3 and 4.15 of the Guide,
and that the terms of the cornerstone investment agreement of TruMed Funds are substantially
the same as the other cornerstone investment agreements;
(d) each of the Company, the Sole Sponsor and the Overall Coordinators has provided the Stock
Exchange with written confirmations in accordance with Chapters 2.3 and 4.15 of the Guide;
and
(e) details of the allocation of the Offer Shares to each of TruMed Funds as a cornerstone
investor in the Global Offering have been disclosed in the allotment results announcement of
the Company.
Such allocations of Offer Shares to the close associates of an existing Shareholder are in
compliance with all the conditions under the consent given by the Stock Exchange.


--- page 20 ---
20
As Placees
The Company has applied, and the Stock Exchange has given, a consent under paragraph 1C(2) of
the Placing Guidelines to permit certain close associates of existing Shareholders to participate in
the Global Offering as placees on the following basis as set out in Paragraph 18 of Chapter 2.3 and
Chapter 4.15 of the Guide, subject to the following conditions:
(a) None of the Permitted Participants, together with the involved existing Shareholder, is, and
will be, a core connected person of the Company, the allocation to the Permitted Participants
will not affect the Company ’s ability to satisfy the public float requirement under Rule
19A.13A of the Listing Rules and the free float requirement under Rule 19A.13C of the
Listing Rules;
(b) each of the Sole Sponsor and the Overall Coordinators confirms that no preferential treatment
in allocation has been, nor will be, given to each of OFC Tech, Changshu Kunsheng
and Changshu Guofa by virtue of their respective relationship with the relevant existing
Shareholders of the Company;
(c) the Company confirms that no preferential treatment in allocation has been, nor will be, given
to each of OFC Tech, Changshu Kunsheng and Changshu Guofa by virtue of their respective
relationship with the relevant existing Shareholders of the Company;
(d) each of the Company, the Sole Sponsor and the Overall Coordinators has provided the Stock
Exchange with written confirmations in accordance with Chapters 2.3 and 4.15 of the Guide;
and
(e) the relevant information in respect of the allocation to the Permitted Participants has been
disclosed in the allotment results announcement.
For details of the allocations of Offer Shares to certain existing Shareholders and/or their close
associates, please refer to the section headed “Allotment Results Details – International Offering –
Allottees with Waivers/Consents Obtained ” in this announcement.


--- page 21 ---
21
Allocation of Offer Shares to Connected Clients
As Cornerstone Investors
The Company has sought, and the Stock Exchange has given, a consent under paragraph 1C(1)
of the Placing Guidelines to allow each of VPHKL and VPL to subscribe for Offer Shares as a
Cornerstone Investor on the following basis as set out in Chapter 4.15 of the Guide, subject to the
conditions as follows:
(a) each of VPHKL and VPL will hold H Shares allocated to it on a discretionary basis and on
behalf of independent third parties;
(b) the relevant cornerstone investment agreement of each of VPHKL and VPL does not contain
any material terms which are more favorable to it than those in other cornerstone investment
agreements;
(c) no preferential treatment has been, nor will be, given to each of VPHKL and VPL by virtue
of its relationship with GF Securities (Hong Kong) Brokerage Limited ( “GF Securities (Hong
Kong) Brokerage ”) in any allocation of Offer Shares in the Global Offering (other than
the assured entitlement under the relevant cornerstone investment agreement following the
principles set out in Chapter 4.15 of the Guide);
(d) GF Securities (Hong Kong) Brokerage has not participated, and will not participate, in the
decision-making process or relevant discussions relating to allocation of Offer Shares to
VPHKL and VPL as cornerstone investors;
(e) each of VPHKL and VPL has confirmed that to the best of its knowledge and belief, it has
not received and will not receive preferential treatment in the allocation of Offer Shares in
the Global Offering as cornerstone investors by virtue of its relationship with GF Securities
(Hong Kong) Brokerage (other than the assured entitlement under the relevant cornerstone
investment agreement following the principles set out in Chapter 4.15 of the Guide);
(f) each of the Company, the Overall Coordinators including GF Securities (Hong Kong)
Brokerage as one of the Overall Coordinators, VPHKL, VPL and GF Securities (Hong Kong)
Brokerage has provided the Stock Exchange with written confirmations in accordance with
Chapter 4.15 of the Guide; and
(g) details of the cornerstone investments and details of the allocations have been disclosed in
the allotment results announcement of the Company.
Such allocations of Offer Shares to connected clients are in compliance with all the conditions
under the consent given by the Stock Exchange.


--- page 22 ---
22
As Placees
Under the International Offering, certain Offer Shares were placed to connected clients of a
connected distributor pursuant to the Placing Guidelines. Details of the placement to connected
clients are set out below.
No. Connected distributor Connected Client
Relationship with the
connected distributor
Basis of
holding
securities
Number
of Offer
Shares
to be
allocated
% of total
Offer
Shares in
the Global
Offering(1)
% of total issued
shares capital
immediately upon
the completion of
Global Offering(1)
1. GF Securities (Hong
Kong) Brokerage
Limited (“GF
Securities (Hong
Kong) Brokerage”)
GF International Investment
Management Limited
(“GF International
Investment”) (2)
GF International Investment
is a member of the same
group of companies as GF
Securities (Hong Kong)
Brokerage.
Discretionary 806,850 5.68% 1.09%
2. E Fund Management Co.,
Ltd. (“E Fund”) (3)
E Fund is a member of the
same group of companies
as GF Securities (Hong
Kong) Brokerage.
Discretionary 57,450 0.40% 0.08%
3. E Fund Management (Hong
Kong) Co., Ltd. (“E Fund
HK”) (3)
E Fund HK is a member
of the same group of
companies as GF Securities
(Hong Kong) Brokerage.
Discretionary 7,100 0.05% 0.01%
4. GF Securities Asset
Management
(Guangdong) Co., Ltd.
(“GF Securities AM”) (4)
GF Securities AM is a
member of the same
group of companies as GF
Securities (Hong Kong)
Brokerage.
Non-
 discretionary
8,500 0.06% 0.01%
5. Orient Securities
(Hong Kong)
Limited (“Orient
Securities”)
Orient Asset Management
(Hong Kong) Limited
(“Orient AM”) (5)
Orient AM is a member of
the same group of Orient
Securities.
Discretionary 800 0.01% 0.001%
Notes:
(1) Assuming the Over-allotment Option is not exercised.
(2) GF International Investment will hold the Offer Shares in its capacity as the discretionary fund manager managing
the funds on behalf of their investors (the “GF International Investment Ultimate Clients ”). GF International
Investment is an indirect non-wholly owned subsidiary of GF Securities Co., Ltd. (ʮ̡) (“GF
Securities”), a company listed on the Shenzhen Stock Exchange (stock code: 000776.SZ) and the Stock Exchange
(stock code: 01776.HK). GF Securities (Hong Kong) Brokerage is an indirect wholly-owned subsidiary of GF
Securities. Accordingly, GF International Investment is a member of the same group of companies as GF Securities
(Hong Kong) Brokerage.
GF International Investment is to invest on a discretionary basis on behalf of the GF International Investment
Ultimate Clients which are independent third parties and no proprietary money is used for the subscribing. To the best
knowledge of GF International Investment, each of GF International Investment Ultimate Clients is an independent
third party of the Company, its subsidiaries, its substantial shareholders, GF International Investment, GF Securities
(Hong Kong) Brokerage and the companies which are members of the same group of companies as GF Securities
(Hong Kong) Brokerage. No ultimate beneficial owner holds 30% or more interest in the funds.


--- page 23 ---
23
GF International Investment is investing on behalf of certain collective investment schemes which are not authorized
by the SFC, details of which are as follow:
Fund Name Fund Manager
Identity of ultimate beneficial owner ( “UBO”)
holding 30% or more interest
Frontline Investment Master SPC
– GF Luminous Fund SP
GF International
Investment
Not applicable as there is no UBO holding 30% or
more interest
Frontline Investment Master SPC
– GF Vision Fund SP
GF International
Investment
Not applicable as there is no UBO holding 30% or
more interest
Frontline Investment Master SPC
– GF Bonanza Fund SP
GF International
Investment
Not applicable as there is no UBO holding 30% or
more interest
Frontline Investment Master SPC
– GF Curation Equity Fund SP
GF International
Investment
Not applicable as there is no UBO holding 30% or
more interest
Frontline Investment Master SPC
– Golden Stone Fund SP
GF International
Investment
Not applicable as there is no UBO holding 30% or
more interest
Frontline Investment Master SPC
– GF Navigation Fund SP
GF International
Investment
Not applicable as there is no UBO holding 30% or
more interest
In addition to the funds disclosed above, GF International Investment is also expected to hold the Offer Shares on
behalf of one SFC authorized fund, namely GFI Global Select Equity Fund.
(3) Each of E Fund and E Fund HK will hold the Offer Shares in its capacity as the discretionary fund manager
managing the sub funds on behalf of the underlying clients (the “E Fund Ultimate Clients ”). GF Securities (Hong
Kong) Brokerage is an indirect wholly-owned subsidiary of GF Securities, which in turn holds 22.65% of the issued
share capital of E Fund. E Fund HK is a wholly-owned subsidiary of E Fund. Therefore, each of E Fund and E Fund
HK constitutes a member of the same group with GF Securities (Hong Kong) Brokerage.
E Fund and E Fund HK are to invest on discretionary basis on behalf of the E Fund Ultimate Clients which are
independent third parties and no proprietary money is used for the subscribing. To the best knowledge of E Fund and
E Fund HK, (i) each of the E Fund Ultimate Clients is an independent third party of the Company, its subsidiaries,
its substantial shareholders, E Fund, E Fund HK, GF Securities (Hong Kong) Brokerage and the companies which
are members of the same group of companies as GF Securities (Hong Kong) Brokerage; and (ii) neither E Fund or E
Fund HK is a collective investment scheme which is not authorised by the SFC.
Details of the E Fund Ultimate Clients are set out below:
Fund Name
Fund
manager
Identity of ultimate beneficial owner
(“UBO”) holding 30% or more interest
E Fund Global Asset Allocation
 Hybrid Fund
E Fund Not applicable as there is no UBO
 holding 30% or more interest.
E Fund Global Healthcare Sector
 Sponsored Hybrid Fund
E Fund Not applicable as there is no UBO
 holding 30% or more interest.
E Fund S&P Global Luxury
 Enhanced Index Fund
E Fund Not applicable as there is no UBO
 holding 30% or more interest.
E Fund (HK) Global Allocation
 Fund SP I
E Fund HK Cinda Sino-Rock Investment Limited, whose
 UBO holding 30% or more interest is China
 Cinda Asset Management Co., Ltd.
 (stock code: 1359.HK).
E FUND (HK) NEO
 OPPORTUNITY SP I
E Fund HK Not applicable as there is no UBO
 holding 30% or more interest.
E Fund (HK) China Equity
 Dividend Fund
E Fund HK Not applicable as there is no UBO
 holding 30% or more interest.


--- page 24 ---
24
(4) GF Securities AM is a direct wholly-owned subsidiary of GF Securities. GF Securities (Hong Kong)
Brokerage is an indirect wholly-owned subsidiary of GF Securities. Accordingly, GF Securities AM is a
member of the same group of companies as GF Securities (Hong Kong) Brokerage.
Each of the ultimate clients of GF Securities AM (the “GF Securities AM Ultimate Clients ”) has engaged
GF Securities AM, an asset manager that is qualified domestic institutional investor as approved by the
relevant PRC authority, in the name of the asset management plans as disclosed below, to subscribe for and
hold the Offer Shares as a placee under the International Offering on behalf of the relevant GF Securities AM
Ultimate Client on a non-discretionary basis. GF Securities AM, in the name of the asset management plans
as disclosed below, will hold the legal title of the Offer Shares, and the economic risks and return of the
Offer Shares will pass through to the GF Securities AM Ultimate Clients.
Details of the GF Securities AM Ultimate Clients are set out as below:
Name of the GF Securities AM Ultimate Clients Name of the asset management plan
Shenwan Hongyuan Group Co., Ltd. ( ͡ຬ҃๕ණ
ʮ̡ , a company listed on the Stock
Exchange (stock code: 6806) and the Shenzhen
Stock Exchange (stock code: 000166))
GF Asset Management Wanxiang No. 1 Single Asset
Management Plan ( ᄿ೯༟၍ຬԮ 1ࠇ
ྌ)
He Wei ( ൭ਃ) GF Asset Management Excellence Diversified
Allocation No. 37 Single Asset Management Plan ( ᄿ
೯༟၍ՙ൳εʩৣໄ 37ྌ )
Zhonghe Capital Cultivation 920 Private Securities
Investment Fund ( ʕձ༟͉ঁঀ920໮ӷ෍ᗇՎҳ
ږwhose ultimate beneficial owner is Zhang
Jingting (ࢬ)
GF Asset Management Hong Kong Equity Diversified
Strategy No. 7 Single Asset Management Plan
To the best knowledge of GF Securities AM, (i) each of the GF Securities AM Ultimate Clients is an
independent third party of the Company, its subsidiaries, its substantial shareholders, GF Securities (Hong
Kong) Brokerage and the companies which are members of the same group of companies as GF Securities
(Hong Kong) Brokerage; and (ii) GF Securities AM is not a collective investment scheme which is not
authorized by the SFC nor is expected to hold the Offer Shares on behalf of such scheme.


--- page 25 ---
25
(5) Orient AM will hold the Offer Shares in its capacity as the discretionary fund manager on behalf of its
underlying clients. Both Orient AM and Orient Securities is a wholly-owned subsidiary of Orient Securities
International Financial Group Limited. Therefore, Orient AM is a member of the same group of Orient
Securities. To the best knowledge of Orient AM, (i) each of the underlying clients of Orient AM is an
independent third party of the Company, its subsidiaries, its substantial shareholders, Orient AM, Orient
Securities and the companies which are members of the same group of companies as Orient Securities; and
(ii) no ultimate beneficial owner holds 30% or more interest in each of the underlying clients of Orient AM,
except that one discretionary account managed by Orient AM, namely Orient Asset Mgt (HK) Ltd-OSR
Selective No.4, is wholly owned by an individual investor who is an independent third party.
Orient AM is investing on behalf of certain collective investment schemes which are not authorized by the SFC,
details of which are as follow:
Fund Name
Types and
values of
assets under
management
Whether
the scheme
is publicly
marketed
Scheme
establishment date
Identities of the general
partners and the 20 largest
limited partners of the
scheme where applicable
Identity of the scheme
administrator
Relationships among
the scheme, the ultimate
beneficial owner(s), Orient
Securities and the Company
Orient Asset Mgt (HK)
 Ltd-OSR Selective
 No.4
Private Fund,
 US$20 million
No August 22, 2024 Not applicable as it is not in
 partnership structure and
 does not have any general
 partner or limited partner
Agricultural Bank of
 China Limited, Hong
 Kong Branch
The scheme and ultimate
 beneficial owners are
 independent third parties
 of Orient Securities, the
 Company and the
 Controlling Shareholders of
 the Company.
ORIENT SUN RISE
 FUND SERIES SPC –
 ORIENT SUN RISE
 OVERSEAS STABLE
 FUND SEGREGATED
 PORTFOLIO
Private Fund,
 US$5 million
No November 18, 2025 Not applicable as it is not in
 partnership structure and
 does not have any general
 partner or limited partner
Agricultural Bank of
 China Limited, Hong
 Kong Branch
The scheme and ultimate
 beneficial owners are
 independent third parties
 of Orient Securities, the
 Company and the
 Controlling Shareholders of
 the Company.
The Company has applied to the Stock Exchange for, and the Stock Exchange has given, a consent
under paragraph 1C(1) of the Placing Guidelines to permit the Company to allocate such Offer
Shares in the International Offering to the connected clients listed above. The allocations of Offer
Shares to such connected clients are in compliance with all the conditions under the consent given
by the Stock Exchange.


--- page 26 ---
26
DISCLAIMERS
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and
Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this
announcement, make no representation as to its accuracy or completeness and expressly disclaim
any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or
any part of the contents of this announcement.
This announcement is not for release, publication, distribution, directly or indirectly, in or into
the United States (including its territories and possessions, any state of the United States and
the District of Columbia) or any other jurisdiction where such distribution is prohibited by law.
This announcement does not constitute or form a part of any offer to sell or solicitation of an
offer to buy, to purchase or subscribe for securities nor shall there be any sale of Offer Shares
in the United States or in any other jurisdictions in which such offer or solicitation would be
unlawful. The securities mentioned herein have not been, and will not be, registered under the
United States Securities Act or any state securities law of the United States. The securities may
not be offered, sold, pledged, or transferred within the United States or to, or for the account
or benefit of U.S. persons (as defined in Regulation S) except pursuant to an exemption from,
or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in
compliance with any applicable state securities laws.
This announcement is for information purposes only and does not constitute an invitation or
offer to acquire, purchase or subscribe for securities of the Company. This announcement is
not a prospectus. Potential investors should read the Prospectus dated May 28, 2026 issued
by LongBio Pharma (Suzhou) Co., Ltd. (ᔼᖹ (ᘽψ)ʮ̡ ) for detailed
information about the Global Offering described below before deciding whether or not to invest
in the Offer Shares.
* Potential investors of the Offer Shares should note that the Sole Sponsor-Overall Coordinator (for itself and
on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong
Kong Underwriting Agreement upon the occurrence of any of the events set out in the paragraph headed
“Underwriting { Underwriting Arrangements {  Hong Kong Public Offering {  Grounds for Termination ”
in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently
expected to be Friday, June 5, 2026).
PUBLIC FLOAT AND FREE FLOAT
Immediately upon completion of the Global Offering (before any exercise of the Over-allotment
Option) and the conversion of Unlisted Shares into H Shares, an aggregate of 33,698,881 H
Shares, representing approximately 45.42% of the total issued share capital of the Company will
be counted towards the public float. Pursuant to Rule 19A.13A(1) of the Listing Rules, where
the expected market value at the time of Listing exceeds HK$6 billion but not exceeding HK$30
billion, the minimum number of H shares held by the public at the time of Listing as a percentage
of the total number of shares in the class to which H shares belong shall be the higher of: (i) the
percentage that would result in the expected market value of H shares held by the public to be
HK$1,500,000,000 at the time of Listing; and (ii) 15%. Based on the Offer Price of HK$96.06 per
Offer Share, the expected market capitalization of the Company ’s H Shares would exceed HK$6
billion and the percentage that would result in the expected market value of H shares held by the
public to be HK$1,500,000,000 at the time of Listing would be 21.05%. Therefore, the Company
will be able to meet the minimum public float requirement under Rule 19A.13A(1) of the Listing
Rules.


--- page 27 ---
27
Under the applicable PRC laws, all existing Shareholders are subject to a lock-up period of
twelve months following the Listing Date. Each of the Cornerstone Investors has agreed to
a lock-up period of six months following the Listing Date. As such, H Shares held by all
existing Shareholders and the Cornerstone Investors are not counted towards the free float of
the H Shares at the time of Listing. Based on the Offer Price of HK$96.06 per Offer Share, the
expected market value of the H Shares held by the public and not subject to disposal restrictions
exceeds HK$600,000,000. As such, the Company satisfies the free float requirement under Rule
19A.13C(1)(b) of the Listing Rules.
The Directors confirm that, immediately following the completion of the Global Offering and
the conversion of Unlisted Shares into H Shares, (i) the three largest public Shareholders do not
hold more than 50% of the H Shares in public hands at the time of Listing in compliance with
Rules 8.08(3) and 8.24 of the Listing Rules; (ii) there will not be any new substantial Shareholder
(as defined in the Listing Rules) immediately after the Global Offering; (iii) no placee will,
individually, be placed more than 10% of the enlarged issued share capital of the Company
immediately after the Global Offering; and (iv) there will be at least 300 Shareholders at the time
of Listing in compliance with Rule 8.08(2) of the Listing Rules.
COMMENCEMENT OF DEALINGS
The H Share certificates will only become valid evidence of title at 8:00 a.m. on Friday, June 5,
2026 (Hong Kong time), provided that the Global Offering has become unconditional and the right
of termination described in the section headed “Underwriting {  Underwriting Arrangements {
Hong Kong Public Offering {  Grounds for Termination ” in the Prospectus has not been exercised.
Investors who trade the H Shares on the basis of publicly available allocation details prior to the
receipt of H Share certificates or prior to the H Share certificates becoming valid evidence of title
do so entirely at their own risk.
Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. on Friday, June
5, 2026 (Hong Kong time), it is expected that dealings in the H Shares on the Stock Exchange will
commence at 9:00 a.m. on Friday, June 5, 2026 (Hong Kong time). The H Shares will be traded in
board lots of 50 H Shares each, and the stock code of the H Shares will be 01779.
By order of the Board
LongBio Pharma (Suzhou) Co., Ltd.
Liu Heng
Chairman of the Board and executive Director
Hong Kong, June 4, 2026
As of the date of this announcement, the Board comprises (i) Dr. LIU Heng, Dr. SUN Bill
Nai-chau and Mr. XIE Ming as executive Directors; (ii) Mr. LIN Jian, Ms. GU Qin, Dr. XUE Di
and Dr. CHEN Kan as non-executive Directors; and (iii) Mr. SIU Paul Yu Hay, Mr. RUAN Tim,
Mr. YANG Chun and Mr. ZHOU Guofang as independent non-executive Directors.